Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Merestinib for Bone Metastases in Breast Cancer
NCT03292536Phase 1Terminated
- Sponsor
- University of Utah
- Start
- Jan 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of merestinib in breast cancer and bone metastases, sponsored by University of Utah. Primary endpoints: Adverse Events that Occur at 12 weeks and Change in urinary N-telopeptide level at 12 weeks. Started Jan 2018; status: terminated.
02
Drugs
merestinib
03
Conditions
breast cancerbone metastases
Beyond the preview
Go deeper on NCT03292536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03292536.